U.S. visual content researchers have created a 3D animation video to inform patients about complex scientific information for a phase 1 clinical trial.
Arkitek Studios of Seattle said animation was used, for the first time, to help patients understand the scientific rationale behind a gene silencing therapy for hepatitis B being developed by Nucleonics Inc.
A review board at one trial site suggested Nucleonics use computer animation to explain the product and its method of action to patients, rather than relying on physicians to explain the complex science underlying the treatment.
The review board's members said use of computer animation would help to ensure the technology was presented to each patient in a consistent manner throughout the trial.
"Informed consent has evolved of necessity in recent years -- patients expect targeted information and feel they deserve to understand the technology surrounding the particular therapy they're being asked to test." said Beth Anderson, Arkitek's chief executive officer. "Most physicians haven't been exposed to this information either, therefore the burden of explanation falls on the company. With time and resources at a premium, this method offers the best way to address questions or concerns patients may have."
Source : http://www.upi.com/
Arkitek Studios of Seattle said animation was used, for the first time, to help patients understand the scientific rationale behind a gene silencing therapy for hepatitis B being developed by Nucleonics Inc.
A review board at one trial site suggested Nucleonics use computer animation to explain the product and its method of action to patients, rather than relying on physicians to explain the complex science underlying the treatment.
The review board's members said use of computer animation would help to ensure the technology was presented to each patient in a consistent manner throughout the trial.
"Informed consent has evolved of necessity in recent years -- patients expect targeted information and feel they deserve to understand the technology surrounding the particular therapy they're being asked to test." said Beth Anderson, Arkitek's chief executive officer. "Most physicians haven't been exposed to this information either, therefore the burden of explanation falls on the company. With time and resources at a premium, this method offers the best way to address questions or concerns patients may have."
Source : http://www.upi.com/
No comments:
Post a Comment